 SOUTH SAN FRANCISCO, Calif., April 10, 2021 GLOBE NEWSWIRE -- Allogene Therapeutics, Inc. Nasdaq: ALLO, a clinical-stage biotechnology company pioneering the development of allogeneic CAR T AlloCAR TTM therapies for cancer, today announced preclinical data at the American Association for Cancer Research AACR Annual Meeting that expands the utility of its TurboCARTM technology platform to address specific biology of solid tumor oncology. 